SuperworthProtara Therapeutics EPS TARA
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2026
- −$1.36
- Latest quarter, Q2 FY26
- −$0.36
- Fiscal year 2025
- −$1.33
Protara Therapeutics' earnings per share was −$1.36 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.36.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.33 | n/a |
| FY2024 | −$2.39 | n/a |
| FY2023 | −$3.57 | −146% |
| FY2022 | $7.77 | +85% |
| FY2021 | $4.20 | n/a |
| FY2019 | −$5.11 | n/a |
| FY2018 | −$45.60 | n/a |
| FY2017 | −$84.80 | n/a |
| FY2016 | −$69.20 | n/a |
| FY2015 | −$52.00 | n/a |
| FY2013 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.36 | n/a | −$1.36 | |
| Q1 FY26 | −$0.31 | n/a | −$1.35 | |
| Q4 FY25 | −$0.38 | n/a | −$1.33 | |
| Q3 FY25 | −$0.31 | n/a | −$1.42 | |
| Q2 FY25 | −$0.35 | n/a | −$1.61 | |
| Q1 FY25 | −$0.29 | n/a | −$1.71 | |
| Q4 FY24 | −$0.47 | n/a | −$2.39 | |
| Q3 FY24 | −$0.50 | n/a | −$2.82 | |
| Q2 FY24 | −$0.45 | n/a | −$3.19 | |
| Q1 FY24 | −$0.97 | n/a | −$3.74 | |
| Q4 FY23 | −$0.90 | −111% | −$3.57 | |
| Q3 FY23 | −$0.87 | n/a | $5.58 |
Against its peers
Companies in Healthcare nearest Protara Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TARAProtara Therapeutics | −$1.36 | |
| PDEXPro DEX | $4.11 | +52% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.71 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Protara Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.